Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Boston Scientific adds MR-safe label to some EU defibs
Boston Scientific said yesterday that it added MR-conditional labeling to the CE Mark for some of the defibrillators it sells in the European Union, claiming the title for Europe’s largest portfolio of MRI-compatible devices.
Marlborough, Mass.-based Boston Scientific said its EL extended longevity and Mini implantable cardiac defibrillators and the X4 cardiac resynchronization therapy defibrillators are now cleared to be labeled with the “ImageReady” brand. The company said the news means that nearly all of its high-voltage cardiac rhythm management devices and leads have MR-conditional clearance in countries recognizing the CE Mark. Read more
2. NuVasive looks to boost manufacturing footprint
NuVasive Inc. said today that it’s planning a significant boost to its manufacturing footprint, scouting locations around the world for a planned, 130,000-square-foot plant.
San Diego-based NuVasive said the plant is expected to employ about 300 workers. A decision on where to site the plant is slated to be made by the end of the year; the company said it hopes to have the facility on line by the end of 2016. Read more
1. TMVI heats up: Medtronic to drop $458m on Twelve’s mitral valve
Medtronic said today that it agreed to pony up as much as $458 million for Twelve Inc. and its transcatheter mitral valve implant, as the race to get a TMVI device to market heats up.
Twelve, a spinout from the Foundry incubator, is based in Redwood City, Calif., is backed by Domain Associates, Versant Ventures, Morgenthaler Ventures, Longitude Capital, Emergent Medical Partners, Vertex Venture Management, and Capital Group, Fridley, Minn.-based Medtronic said. Read more